Pages that link to "Q37117151"
Jump to navigation
Jump to search
The following pages link to Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer (Q37117151):
Displaying 50 items.
- Changing strategies for target therapy in gastric cancer (Q26774513) (← links)
- National consensus in China on diagnosis and treatment of patients with advanced breast cancer (Q26775621) (← links)
- Targeted Therapies in Triple-Negative Breast Cancer (Q26777736) (← links)
- Quantification of HER family receptors in breast cancer (Q27015506) (← links)
- Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk (Q27315979) (← links)
- Breast cancer chemoprevention: old and new approaches (Q27693259) (← links)
- Twenty years of anti-HER2 therapy-associated cardiotoxicity (Q28079391) (← links)
- Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis (Q28547354) (← links)
- Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. (Q30249335) (← links)
- Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors (Q33352155) (← links)
- Hematologic toxicities of small molecule tyrosine kinase inhibitors (Q33398485) (← links)
- The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer (Q33409083) (← links)
- Are current drug development programmes realising the full potential of new agents? The scenario (Q33555569) (← links)
- Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme (Q33561588) (← links)
- Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients (Q33579653) (← links)
- Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life (Q33703527) (← links)
- Optimizing Collection of Adverse Event Data in Cancer Clinical Trials Supporting Supplemental Indications (Q33710475) (← links)
- An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. (Q33777427) (← links)
- Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines (Q33822560) (← links)
- New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis (Q33841512) (← links)
- Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin (Q33869726) (← links)
- PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib (Q33933626) (← links)
- Modeling the relationship between progression-free survival and overall survival: the phase II/III trial (Q34040130) (← links)
- RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. (Q34048144) (← links)
- Understanding resistance to EGFR inhibitors-impact on future treatment strategies (Q34088424) (← links)
- Lapatinib – Member of a New Generation of ErbB-Targeting Drugs (Q34096228) (← links)
- Safety Profile and Clinical Recommendations for the Use of Lapatinib (Q34096239) (← links)
- Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib (Q34241118) (← links)
- Targeting HER2 in breast cancer: overview of long-term experience (Q34272044) (← links)
- Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. (Q34354224) (← links)
- Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. (Q34417920) (← links)
- Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report (Q34427231) (← links)
- Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study (Q34493571) (← links)
- Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)–paclitaxel nanoparticles (Q34513963) (← links)
- Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel (Q34547436) (← links)
- Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. (Q34620222) (← links)
- Hunk is required for HER2/neu-induced mammary tumorigenesis (Q34627179) (← links)
- The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study (Q34717298) (← links)
- Updated UK Recommendations for HER2 assessment in breast cancer (Q35048548) (← links)
- Targeting the HER/EGFR/ErbB family to prevent breast cancer. (Q35208654) (← links)
- Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation (Q35284749) (← links)
- Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial (Q35584284) (← links)
- Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. (Q35599781) (← links)
- Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective (Q35617654) (← links)
- Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. (Q35625995) (← links)
- Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer (Q35653820) (← links)
- Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer (Q35661968) (← links)
- Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. (Q35687574) (← links)
- Treatment of HER2-positive breast cancer. (Q35740877) (← links)
- Efficacy and tolerability of lapatinib in the management of breast cancer (Q35835926) (← links)